Imaging Habitats in Sarcoma
肉瘤的成像栖息地
基本信息
- 批准号:9461334
- 负责人:
- 金额:$ 24.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-01 至 2019-07-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAffectAlgorithmsAreaBiochemistryBlood CellsCarcinomaCaringCell DensityCell LineChildChildhoodClinicClinicalConnective TissueData SetDiffusionDiseaseDisease remissionDoseDoxorubicinDrug TargetingEnvironmentEvaluationExcisionHabitatsHalf-LifeHistologicHistologyHypoxiaImageImmunohistochemistryIn VitroIndividualIntentionMagnetic Resonance ImagingMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of pancreasMalignant neoplasm of prostateMeasurableMeasuresMesenchymalMetabolicMethodsMolecularMolecular ProfilingMonitorMorphologyMusNew AgentsOxygenOxygen ConsumptionPatientsPerfusionPharmaceutical PreparationsPhenotypePhysiologic pulsePhysiologicalPhysiologyPlasmaPreclinical TestingProdrugsProgression-Free SurvivalsPyruvateRadiology SpecialtyScanningScheduleSoft tissue sarcomaSolid NeoplasmTestingTherapeuticTherapeutic EffectTherapy trialTissuesToxic effectTranslatingTumor TissueTumor stageUncertaintyUnresectableVascular blood supplyWorkbasecancer cellchemotherapycontrast enhancedexpectationflexibilityimaging biomarkerimprovedin vivomalignant breast neoplasmnovel drug classpatient stratificationphase III trialpre-clinicalpredicting responsepredictive markerprogramspublic health relevanceresponsesarcomatreatment planningtreatment strategytrial designtumorvirtual
项目摘要
DESCRIPTION (provided by applicant): Soft tissue sarcomas (STS) are a heterogeneous group of mesenchymal tissue cancers, with over 50 histological sub-types. Regardless of type, virtually all STS are treated the same; i.e. with doxorubicin (DOX) followed by resection, if possible. More than 20% of STS are non-resectable and, of those that are, more than 20% recur. For non-resectable or recurring patients, median survival is a dismal 18 months. Perhaps because of its rarity, no new front-line agents have been developed for STS in decades. Among newer agents being developed for STS, TH-302 is showing exceptional promise. TH-302 is an alkylating pro-drug that is activated only in regions of severe hypoxia, and is currently in a phas III trial in combination with DOX in unresectable STS. The primary endpoint of this trial is overal survival with a secondary endpoint of objective radiological response with RECIST 1.1. RECIST responses rarely correlate with survival responses in soft tissue sarcomas, however. The purpose of this work is to develop MR imaging biomarkers that can predict response to DOX and/or TH-302, with the overarching hypothesis that distinct MRI-defined sub-regions of tumors will have differential responses to these agents. Because these sub-regions are defined by their distinct physiology illuminated by combining multiple MR scans, we have termed these as distinct "habitats". Because TH-302 is active only in hypoxia, and hypoxia should be represented by a specific habitat, we specifically hypothesize that imaging of the hypoxic habitat can be used to predict and monitor responses to TH-302. The hypoxia habitat is classified as having low perfusion and high cell density. In contrast, the DOX-responsive habitat should be well perfused (yielding higher drug concentrations) and have high cell density (with more drug targets). This represents a conceptual advance as such habitats may provide a common predictive biomarker across the multiple histological sub-types of STS for patient stratification and therapeutic decision support. The approach will follow on preliminary work, wherein delineated habitats were quantitatively identified across multiple histological types and grades of
STS by combining T1, contrast- enhanced T1, and T2 STIR MR images. The current proposal is entirely pre-clinical, with the expectation that findings herein can be rapidly translated to clinial care. Preclinical work is justified in that there is greater flexibility to interrogate a wider porfolio of MRI pulse sequences and treatment strategies that can be related to underlying histology and molecular profiling. Aim 1 will quantitatively compare MR-visible habitats to histology and molecular profiles of xenotransplanted tumors. Aim 2 will test the hypothesis that tumors with different habitat profiles will be differentially responsive to DOX and/or TH-302. In Aim 3, we wil investigate the effects of metabolic perturbations to affect the hypoxic habitat and thus improve response to TH-302. At the end of this study, we will have developed a new set of MR imaging biomarkers for predicting and monitoring response in this heterogeneous group of diseases, with the expectation that these finding will inform a follow-on study in the clinic.
描述(由申请人提供):软组织肉瘤(STS)是一组异质性间叶组织癌,具有超过50种组织学亚型。无论哪种类型,几乎所有STS的治疗方法都是相同的;即使用阿霉素(DOX),然后切除,如果可能的话。超过20%的STS是不可切除的,并且在那些不可切除的STS中,超过20%复发。对于不可切除或复发的患者,中位生存期为18个月。也许是因为它的稀有性,几十年来没有为STS开发新的前线代理商。在为STS开发的新药剂中,TH-302显示出非凡的前景。TH-302是一种烷基化前药,仅在严重缺氧区域活化,目前正在与DOX联合治疗不可切除STS的III期临床试验中。本试验的主要终点是总生存期,次要终点是客观放射学缓解(RECIST 1.1)。然而,在软组织肉瘤中,RECIST反应很少与生存反应相关。这项工作的目的是开发可以预测对DOX和/或TH-302的反应的MR成像生物标志物,其总体假设是不同的MRI定义的肿瘤子区域将对这些药物具有不同的反应。因为这些子区域是由它们通过结合多个MR扫描而照亮的不同生理学来定义的,所以我们将这些称为不同的“栖息地”。因为TH-302仅在缺氧中有活性,并且缺氧应该由特定的栖息地表示,我们特别假设缺氧栖息地的成像可以用于预测和监测对TH-302的反应。缺氧生境被分类为具有低灌注和高细胞密度。相比之下,DOX反应的栖息地应该是灌注良好的(产生更高的药物浓度),并具有高细胞密度(具有更多的药物靶点)。这代表了概念上的进步,因为这种栖息地可以在STS的多种组织学亚型中提供共同的预测生物标志物,用于患者分层和治疗决策支持。该方法将遵循的初步工作,其中划定的栖息地定量确定跨多种组织学类型和等级的
通过结合T1、对比增强T1和T2 STIR MR图像进行STS。目前的建议完全是临床前的,期望本文的发现可以迅速转化为临床护理。临床前工作是合理的,因为有更大的灵活性来询问更广泛的MRI脉冲序列和治疗策略,可以与潜在的组织学和分子谱。目的1将定量比较MR可见的栖息地异种移植肿瘤的组织学和分子特征。目的2将检验具有不同生境特征的肿瘤将对DOX和/或TH-302有差异性响应的假设。在目标3中,我们将研究代谢扰动影响缺氧生境的作用,从而改善对TH-302的反应。在本研究结束时,我们将开发一套新的MR成像生物标志物,用于预测和监测这种异质性疾病组的反应,并期望这些发现将为临床后续研究提供信息。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robert J. Gillies其他文献
Causes, consequences, and therapy of tumors acidosis
- DOI:
10.1007/s10555-019-09792-7 - 发表时间:
2019-03-26 - 期刊:
- 影响因子:8.700
- 作者:
Smitha R. Pillai;Mehdi Damaghi;Yoshinori Marunaka;Enrico Pierluigi Spugnini;Stefano Fais;Robert J. Gillies - 通讯作者:
Robert J. Gillies
Why do cancers have high aerobic glycolysis?
为什么癌症具有高有氧糖酵解?
- DOI:
10.1038/nrc1478 - 发表时间:
2004-11-01 - 期刊:
- 影响因子:66.800
- 作者:
Robert A. Gatenby;Robert J. Gillies - 通讯作者:
Robert J. Gillies
Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis?
- DOI:
10.1007/s10863-007-9085-y - 发表时间:
2007-07-12 - 期刊:
- 影响因子:3.000
- 作者:
Robert J. Gillies;Robert A. Gatenby - 通讯作者:
Robert A. Gatenby
A microenvironmental model of carcinogenesis
致癌作用的微环境模型
- DOI:
10.1038/nrc2255 - 发表时间:
2008-01-01 - 期刊:
- 影响因子:66.800
- 作者:
Robert A. Gatenby;Robert J. Gillies - 通讯作者:
Robert J. Gillies
Promise and Progress for Functional and Molecular Imaging of Response to Targeted Therapies
- DOI:
10.1007/s11095-007-9250-3 - 发表时间:
2007-03-24 - 期刊:
- 影响因子:4.300
- 作者:
Renu M. Stephen;Robert J. Gillies - 通讯作者:
Robert J. Gillies
Robert J. Gillies的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Robert J. Gillies', 18)}}的其他基金
Imaging Acidosis and Immune Therapy in PDAC
PDAC 中的影像学酸中毒和免疫治疗
- 批准号:
10088425 - 财政年份:2020
- 资助金额:
$ 24.99万 - 项目类别:
Imaging Acidosis and Immune Therapy in PDAC
PDAC 中的影像学酸中毒和免疫治疗
- 批准号:
9896558 - 财政年份:2020
- 资助金额:
$ 24.99万 - 项目类别:
Molecular-Lab Radiopharmaceutical Synthesis System
分子实验室放射性药物合成系统
- 批准号:
8640558 - 财政年份:2014
- 资助金额:
$ 24.99万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 24.99万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 24.99万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 24.99万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 24.99万 - 项目类别:
Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 24.99万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 24.99万 - 项目类别:
Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 24.99万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 24.99万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 24.99万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 24.99万 - 项目类别:
Grant-in-Aid for Early-Career Scientists